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Abstract 26 
Dental caries is a highly prevalent disease caused by colonisation of tooth surfaces by 27 
cariogenic bacteria, such as Streptococcus sobrinus and S. salivarius. Reducing initial 28 
adherence of such bacteria to teeth may delay onset of caries. Many foods, such as 29 
milk, can inhibit microbial adherence. In this investigation, the effect of untreated 30 
(UT) and enzyme-treated (ET) dairy powders on adherence of S. sobrinus and S. 31 
salivarius to hydroxylapatite (HA), an analogue of tooth enamel, was examined. UT 32 
acid whey protein concentrate (WPC) 80 inhibited streptococcal adherence to 33 
phosphate-buffered saline-coated HA (PBS-HA) and saliva-coated HA (S-HA) by 34 
>80% at ≥31.25μg mL-1. UT sweet WPC80, buttermilk powder and cream powder 35 
also significantly reduced adherence (P<0.05). Enzyme-treatment of all dairy powders 36 
reduced their anti-adhesion activity. However, ET sweet WPC80 significantly 37 
inhibited growth of these streptococci (P<0.05) at ≥0.6mg mL-1. Therefore, dairy 38 
powders may reduce progression of dental caries by their anti-adhesion and /or 39 
antibacterial activity. 40 
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1. Introduction 50 
Dental caries is a bacterial disease characterised by a localised progressive, 51 
molecular disintegration of the tooth (Marcotte and Lavoie, 1998). Tooth decay and 52 
periodontal disease are among the most common bacterial infections in humans 53 
(Loesche, 1986), affecting both children and adults (Aas et al., 2005). The main 54 
etiological agents of human dental caries are the mutans streptococci, such as 55 
Streptococcus sobrinus (Loimaranta et al., 1997), a strongly acidogenic bacterium 56 
(Nascimento et al., 2004). Though it is not a member of the mutans streptococci, 57 
Streptococcus salivarius is also associated with formation of dental caries (Becker et 58 
al., 2002). S. salivarius is one of the earliest colonisers of the oral cavity following 59 
birth (Carlsson et al., 1970), and has long been recognised as a ‘potent acid producer’ 60 
(Shiere et al., 1951). In addition to causing dental caries, microorganisms inhabiting 61 
the oral cavity can be introduced into the bloodstream, leading to occurrence of ‘focal 62 
oral infections’, including bacteremia, endocarditis and meningitis (Gendron et al., 63 
2000, Reif et al., 2009).  64 
Adherence to oral mucosa and tooth surfaces is a vital step for bacterial 65 
colonisation of the oral cavity, as adherence provides resistance to salivary flow 66 
(Marcotte and Lavoie, 1998). In the 1970’s Liljemark and co-workers proposed that 67 
the initial colonisation of the tooth surface was of utmost importance when attempting 68 
to prevent or control formation of dental plaque (Liljemark et al., 1978). In recent 69 
years, many foods and beverages such as water-soluble protein-fraction (WSPF) of 70 
hen egg yolk (Gaines et al., 2003), cranberry constituents (Yamanaka et al., 2004), 71 
barley coffee (Papetti et al., 2007) and herbal extracts (Limsong et al., 2004, Chen et 72 
al., 2005) have been found to reduce adherence of caries-causing bacteria to tooth 73 
surfaces. Human milk represents a classic example of how dietary constituents are 74 
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capable of reducing bacterial adherence (Ofek et al., 2003). It is not unreasonable to 75 
speculate that the equivalent components of bovine milk and milk-derived products, 76 
such as whey, may also possess adherence inhibitory properties.  77 
Addition of rennin or acid to milk causes the casein proteins to coagulate, 78 
while the remaining liquid phase is referred to as whey (Zadow, 1994). The main 79 
constituents of whey include protein, lactose, vitamins, minerals and traces of milkfat 80 
(Anonymous, 2003). Whey proteins are recognised as having both nutritional and 81 
functional properties (Smithers, 2008), but some biologically active peptides 82 
harboured within these proteins are latent until they are liberated by the action of 83 
hydrolytic enzymes (Sinha et al., 2007). Peptides exhibiting antimicrobial properties 84 
have been isolated from whey proteins such as β-lactoglobulin, α-lactalbumin and 85 
lactoferrin following proteolysis (Lopez-Exposito and Recio, 2006).  86 
The milkfat component of whey may also possess antimicrobial activity. 87 
Bovine milkfat contains a broad range of fatty acids varying in chain length and 88 
degree of saturation (Jensen and Newburg, 1995). In the 1970’s, researchers reported 89 
that the antimicrobial action observed for milkfat was dependent on the release of free 90 
fatty acids and monoglycerides by the hydrolytic action of lipases (Sun et al., 2002). 91 
Generally, Gram positive microorganisms (such as streptococci) are lipid sensitive 92 
whereas Gram negatives are not (Kabara et al., 1972), but some exceptions to this 93 
trend exist (Sprong, 2002).  94 
Considering these points, it is evident that both the protein and milkfat 95 
constituents of whey may have the potential to inhibit cariogenic bacteria, particularly 96 
following enzyme treatment. Further to this, it has been reported that some bioactive 97 
peptides derived from dairy proteins can possess multi-functional properties (Haque 98 
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and Chand, 2008). Thus, in addition to antibacterial peptides, hydrolysis of whey 99 
proteins may lead to production of peptides possessing anti-adhesion activity.  100 
Research carried out in this laboratory (Halpin et al., 2008) has shown that a 101 
range of untreated dairy powders reduced adherence of the cariogenic bacterium S. 102 
mutans to hydroxylapatite, a calcium-phosphate analogue of human tooth enamel 103 
(Gibbons et al., 1976, Clark and Gibbons, 1977). Further to this, more recent research 104 
carried out by this group has shown that dairy powders pre- and post-hydrolysis can 105 
inhibit adhesion of S. mutans to HA, and that enzyme treated SWPC80 inhibits 106 
growth of this microorganism (Halpin et al., 2011). The aims of the present study 107 
were firstly to assess the effects of various untreated and enzyme-treated dairy 108 
products on the adherence of S. sobrinus and S. salivarius to hydroxylapatite. 109 
Adherence was examined in the presence and absence of saliva. In addition, the effect 110 
of enzyme-treated sweet whey protein concentrate on the growth of these cariogenic 111 
streptococci was examined.  112 
2. Materials and Methods  113 
2.1 Bacterial Isolates and Growth Conditions  114 
S. sobrinus (DSM 20742) was obtained from the German Collection of 115 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). S.  salivarius 116 
(2184 D41287), a clinical isolate, was kindly donated by Professor Martin Cormican, 117 
Microbiology Department, National University of Ireland, Galway.   118 
Both strains were maintained on Protect™ Bacterial Preserve beads (Technical 119 
Service Consultants Ltd, Lancashire, UK) at -80˚C. A single bead from the frozen 120 
stock culture was used to inoculate a Columbia blood agar plate (CBA: Oxoid, 121 
Hampshire, England) and grown aerobically at 37˚C for 48 h. A single colony from 122 
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the blood agar plate was subsequently used to inoculate 20mL of brain heart infusion 123 
(BHI) broth (BHI Broth: LabM, Lancashire, UK) and grown under aerobic conditions 124 
without shaking at 37˚C for 18 h. 125 
2.2 Source and Characterisation of Dairy Powders  126 
Sweet whey protein concentrate (SWPC80), acid WPC 80 (AWPC80), sweet WPC 35 127 
(SWPC35), whey protein isolate (WPI), whey powder (WP) and demineralised whey 128 
(DW) powders were supplied by Carbery Milk Products (Ballineen, Cork, Ireland). 129 
Buttermilk powder (BMP) and cream powder (CP) were supplied by Kerry Group plc 130 
(Tralee, Co. Kerry, Ireland). Albumin from chicken egg white (grade V) was supplied 131 
by Sigma (Poole, Dorset, UK).  132 
Compositional analysis was performed on each dairy product using standard methods. 133 
Ash content was analysed according to Malkomesius & Nehring (1951). Fat content 134 
was determined according to the method of Röse-Gottlieb (International Dairy 135 
Federation, IDF, 1987), protein content was determined by the Kjeldahl method (IDF, 136 
1993) and the moisture content was determined by the IDF reference method (IDF, 137 
1993). 138 
2.3 Hydrolysate Preparation Conditions 139 
Crude porcine pancreatic lipase (PPL, 100-400 units/ mg protein) (Sigma, Poole, 140 
Dorset, England) was used throughout the study. Hydrolysates were prepared in a 141 
Fermac 200 fermentor (Electrolab Ltd, Tewkesbury, UK) as follows: a c. 2% (w/v) 142 
solution of substrate was prepared by dissolving 20g of dairy powder in 900mL of 143 
sterile distilled water and heating at 37˚ C with stirring for 30 min. Lipase solution (1g 144 
of PPL in 100mL of sterile H20) was added to the substrate solution to give a final 145 
incubation volume of 1 L. The substrates were then incubated for 18 h at 37˚C with 146 
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stirring. The resulting hydrolysates were heated at 60˚C for 10 min in order to 147 
denature the enzyme(s). Each hydrolysate was then placed on ice and allowed to cool 148 
to less than 10˚C (approx. 45 min), before being frozen using liquid nitrogen and 149 
subsequently lyophilised (Moduloyo, Edwards High Vacuum, Manor Royal, Crawley, 150 
Sussex, UK).  151 
2.4 Adhesion Assay 152 
 2.4.1 Preparation of Hydroxylapatite 153 
Hydroxylapatite (HA) beads were supplied by Merck (Darmstadt, Germany). Both 154 
buffer-coated and saliva-coated HA were used throughout the study Particle size 155 
analysis using a Malvern Mastersizer (Malvern Instruments Ltd., Worcestershire, UK) 156 
showed the average diameter (D [4,3]) of the HA beads to be approximately 10μm. 157 
Phosphate-buffered saline coated HA (PBS-HA, PBS: Oxoid, Hampshire, England) 158 
was prepared by suspension of 7.5mg mL-1 HA in PBS immediately before use in the 159 
adherence assays.  160 
Saliva-coated-HA (S-HA) was prepared similarly to the protocol set out by Gibbons 161 
and Etherden (1982) as follows: parafilm-stilumated whole saliva was collected in an 162 
ice-chilled tube from two healthy donors (1 male, 1 female) at least 1 h after eating, 163 
drinking or brushing of teeth. The saliva was heated at 60ºC for 30 min to inactivate 164 
degenerative enzymes, and subsequently centrifuged at 12,000 × g for 15 min. The 165 
pellet was discarded and the supernatant (i.e. clarified whole saliva) was used to 166 
prepare a 7.5mg mL-1 dispersion of HA. Aliquots (150μL) of this dispersion were 167 
dispensed into the wells of a 96-well V-bottomed plate (Sarstedt, Newton, North 168 
Carolina, USA), and incubated at 30ºC for 1 h with gentle agitation (4.5 × g). 169 
Following this, the microtitre plate was centrifuged at 805 × g for 2 min, the 170 
supernatants discarded and the S-HA pellets washed twice with sterile pre-warmed 171 
 8 
PBS to remove excess saliva. The S-HA pellets were subsequently resuspended in 172 
sterile PBS for use in the adherence assay. 173 
2.4.2 Preparation of Syto 13 dye 174 
Syto 13 dye (Molecular Probes, Oregon, USA) was supplied as a 5mM solution in 175 
dimethylsulphoxide (DMSO). This concentration was adjusted to 5μM by appropriate 176 
dilution in sterile PBS, and was used only on the day of preparation. Standard curves 177 
were constructed to show the relationship between relative fluorescent units (RFU) 178 
and colony forming units per millilitre (CFU mL-1) for S. sobrinus and S. salivarius, 179 
which had correlation coefficient values (R2) of 0.993 (Figure 1(a)) and 0.989 (Figure 180 
1(b)), respectively. 181 
2.4.3 Assay Protocol 182 
Overnight cultures of S. sobrinus and S. salivarius were subjected to centrifugation at 183 
3220 × g (Eppendorf 5810R, Cambridge, UK) for 10 min and each of the pellets were 184 
washed once in sterile PBS. Following a second centrifugation step, the bacterial 185 
pellets were re-suspended in PBS, and the OD630nm of the suspensions measured using 186 
a Multiskan Ascent spectrophotometer, and adjusted to 0.2 by appropriate dilution 187 
with sterile PBS.  188 
The adherence assays were carried out as previously described (Halpin et al., 2008, 189 
Halpin et al., 2011), using sterile 96-well polystyrene microtitre half-area plates 190 
(Nunc, Roskilde, Denmark). Dairy powders were prepared to the required 191 
concentration by dispersing the dried powder in PBS. Briefly, 50μL of test material 192 
solution at various concentrations was added to the wells, followed by 50μL of PBS-193 
HA or S-HA (7.5 mg mL-1). Bacterial suspension (50μL) was added to the wells, so 194 
that the final volume of each well was 150μL. Control wells (no bacteria and/ or no 195 
HA) were included in each assay. The plate was incubated at room temperature for 45 196 
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min, and manually inverted at 5 min intervals to prevent settling of the HA 197 
suspension. The plate was subsequently centrifuged at 201 × g to sediment the HA 198 
and any adhering bacteria, leaving the non-adhering bacteria in suspension. These 199 
non-adhering bacteria were labelled with 10μL of 5μmol L-1 Syto® fluorescent dye. 200 
For more information regarding the development and validation of the assay described 201 
here, the reader should refer to Halpin et al., 2008. 202 
2.5 Quantification of Bacterial Adherence  203 
Aliquots (100μL) of supernatant from the adherence assay containing the non-204 
adhering bacteria were transferred from each well of the half-area plate to the 205 
corresponding wells of a black microtitre plate (Costar, Corning Inc., Corning, USA). 206 
This plate was allowed to stand at room temperature for 5 min in the dark before 207 
reading the fluorescence using a Fluoroskan Ascent plate reader (Thermo Electron 208 
Corporation, Finland). The excitation wavelength was 485 nm and the emission 209 
intensity was monitored at 538 nm. Three measurements were taken at 5 min 210 
intervals, and the average fluorescence calculated. The fluorescence due to the 211 
number of bacteria present in the supernatant was determined as a direct readout from 212 
the fluorimeter as relative fluorescent units (RFU). The background fluorescence due 213 
to non-bacterial components of the assay (i.e. dairy powder and HA) were subtracted.  214 
The percentage inhibition of adhesion was calculated as follows: 215 
( )
( )
Fluorescence due to unbound bacteria
Fluorescence due tototal input bacteria
× 100                   (1) 216 
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2.6 Growth Assays 217 
Growth assays were carried out in sterile 96-well plates (Nunc, Roskilde, Denmark). 218 
Overnight cultures of S. sobrinus and S. salivarius were prepared in BHI broth as 219 
described earlier (section 2.1).  220 
A working culture containing c. 108 colony forming units per millilitre (CFU mL-1) 221 
was prepared by adding 1mL of overnight culture to 9mL of sterile BHI broth. Test 222 
materials were prepared by dispersing dried dairy powders or hydrolysates in BHI 223 
broth to the desired concentration. Aliquots (100μL) of test material were added to the 224 
wells of the plate, followed by 100μL of the diluted culture; the final concentrations 225 
of test material were 0.6mg mL-1, 1.25mg mL-1, 2.5mg mL-1 and 5mg mL-1. Bacterial 226 
growth in the absence of test material (i.e. control growth) was also determined. The 227 
plate was then incubated at 37˚C for 18 h in a Multiskan Ascent plate reader (Thermo 228 
Electron Corporation, Finland). Immediately prior to incubation the plate was shaken 229 
for 1 min in order to disperse the suspensions. The optical density (OD) readings at 230 
630nm for each well were subsequently recorded at 1 h intervals, with the plate being 231 
shaken for 30 s immediately prior to measurement. The initial OD630nm reading, 232 
recorded at time 0, of each well was subtracted from all other readings for the 233 
corresponding wells over the 18 h incubation time (i.e. to subtract the background 234 
OD630nm values). Growth inhibition (%) of S. sobrinus and S. salivarius due to the 235 
presence of dairy powder was calculated using OD630nm values at mid-stationary phase 236 
according to the following equation: 237 
( ) ( )
( )
OD Control Growth OD Growth in Presence of Dairy Powder
OD Control Growth
 −  ×100 (2) 238 
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2.7 Statistical Analysis 239 
All growth / adherence assays were performed at least three times (n=3). Results were 240 
expressed as the mean ± standard deviation (S.D.). Differences between 241 
concentrations within treatments were determined using least significant difference 242 
(LSD) test, while differences between treatments were determined using Duncan’s 243 
test. Both analyses were performed using SAS Version 9.1.3. Data were considered 244 
significantly different if P<0.05.  245 
3. Results  246 
Compositional analysis of protein, fat, moisture, ash and lactose content of each dairy 247 
powder was determined, and is summarised in Table 1. These were typical of their 248 
product types.  249 
3.1 Adherence Assays  250 
Standard curves were constructed to show the relationship between relative 251 
fluorescent units (RFU) and colony forming units per millilitre (CFU mL-1) for S. 252 
sobrinus and S. salivarius, and are shown in Figure 1 (a) and (b), respectively.  253 
3.1.1 S. sobrinus  254 
(i) Adherence to Phosphate-Buffered Saline-Coated Hydroxylapatite (PBS-HA) 255 
Typically, c. 28% of any given culture of S. sobrinus used throughout this study did 256 
not adhere to PBS-HA in the absence of test material (‘control’ in Table 2).  257 
Of the UT dairy powders, AWPC80 was the most effective inhibitor of S. sobrinus 258 
adherence to PBS-HA at 31.25µg mL-1 and 62.5µg mL-1 (P<0.05).  At 62.5μg mL-1, 259 
UT SWPC80, UT BMP and UT CP showed a significant concentration dependent 260 
increase (P<0.05), and at the maximum concentration examined (125μg mL-1) UT 261 
AWPC80, UT SWPC80, UT BMP and UT CP were found to be equally effective 262 
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(P<0.05).  Of the untreated dairy powders, WPI, WP and DW were the poorest 263 
inhibitors of S. sobrinus adherence to PBS-HA at all concentrations. 264 
Following enzyme-treatment, the anti-adhesion activity of all powders was reduced. 265 
At 31.25µg mL-1, all ET dairy powders were only equally as effective as the protein 266 
control, egg albumin (P>0.05). ET BMP was significantly (P<0.05) the most effective 267 
inhibitor at 62.5μg mL-1 and 125μg mL-1. ET SWPC35, WPI, WP and DW had no 268 
inhibitory effect on adherence of S. sobrinus to PBS-HA at any concentration, relative 269 
to the control (P>0.05). The loss in anti-adhesion activity due to enzyme-treatment 270 
was most noticeable at the highest concentration (125μg mL-1), with all powders 271 
(except WP) being significantly (P<0.05) less effective when compared to its 272 
equivalent untreated form. 273 
(ii) Adherence to Saliva-Coated Hydroxylapatite (S-HA) 274 
For the adherence assays carried out using S. sobrinus, c. 46% of microorganisms in 275 
any given culture did not adhere to S-HA under our assay conditions (‘control’ in 276 
Table 3). This value was markedly higher than the control level observed for PBS-277 
HA.  278 
The egg albumin protein control inhibited adherence of S. sobrinus to S-HA to a 279 
greater extent than UT SWPC35, UT WP and UT DW at 31.25µg mL-1 (P<0.05), with 280 
UT SWPC35 actually significantly (P<0.05) promoting adherence. This was also 281 
evident for UT WP and UT DW at 62.5µg mL-1. At 125µg mL-1, UT SWPC80, UT 282 
AWPC80, UT WPI and UT CP appeared to be the most effective inhibitors of 283 
adherence of S. sobrinus to S-HA and exhibited similar levels of activity, yet these 284 
values were not significantly different from those observed for egg albumin (P>0.05). 285 
For the enzyme-treated dairy powders, at maximum concentration (125μg mL-1), only 286 
ET AWPC80 was significantly more effective than egg albumin (P<0.05). Also, at 287 
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this concentration ET WPI, ET DW and ET CP did not reduce adherence of S. 288 
sobrinus to S-HA relative to the control (P>0.05). However, at 125μg mL-1 ET 289 
AWPC80, ET SWPC80 and ET BMP significantly inhibited adherence of S. sobrinus 290 
to S-HA, causing the non-binding population of bacteria to increase to ≥ 80%. 291 
3.1.2 S. salivarius 292 
(i) Adherence to PBS-HA 293 
Approximately 41% of any given culture of S. salivarius used throughout this study 294 
did not adhere to PBS-HA in the absence of test material (‘control’ in Table 4). 295 
With the exception of DW, at 31.25µg mL-1 all of the UT test materials (including egg 296 
albumin) significantly (P<0.05) reduced adherence of S. salivarius to PBS-HA 297 
relative to the control. At 31.25µg mL-1, UT AWPC80, UT WP and UT BMP 298 
exhibited similar levels of inhibition of S. salivarius adhesion to PBS-HA (resulting in 299 
a non-binding population of 85-90%) and were significantly (P<0.05) more potent 300 
than the other untreated test materials. UT AWPC80, UT WPI, UT BMP and UT CP 301 
were equally as effective at 62.5µg mL-1 and 125 µg mL-1 (P>0.05). However, UT 302 
SWPC80 showed an equivalent level of anti-adhesion activity at 125µg mL-1. Also at 303 
this concentration (125μg mL-1), all UT powders were more effective than the protein 304 
control, egg albumin (P<0.05). 305 
Subjecting the dairy powders to enzyme treatment reduced their ability to inhibit 306 
adherence of S. salivarius to PBS-HA. No significant difference was found between 307 
any ET test materials (P>0.05); furthermore, no ET dairy powder was more effective 308 
than the protein control, egg albumin (P>0.05).  309 
(ii) Adherence to S-HA 310 
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Due to the large non-binding population of S. salivarius to S-HA (c. 66%) it was 311 
difficult to establish the efficacy of test materials in reducing adherence of this 312 
microorganism to S-HA (Table 5). 313 
At 31.25µg mL-1, only UT SWPC80 and UT AWPC80 were found to be more potent 314 
inhibitors of S. salivarius adhesion to S-HA than egg albumin (P<0.05). However, at 315 
62.5µg mL-1 and 125μg mL-1, all test materials (including egg albumin) showed equal 316 
levels of efficacy (P>0.05).  317 
Following enzyme-treatment, many of the hydrolysed dairy powders significantly 318 
(P<0.05) inhibited adherence of S. salivarius to S-HA relative to the control, but only 319 
ET WPI was found to be more effective than egg albumin (P<0.05).  At 31.25µg mL-320 
1, ET CP was the least effective inhibitor of S. salivarius adherence to S-HA (P<0.05). 321 
No ET test material was more effective than egg albumin (P>0.05) at 62.5µg mL-1 322 
and 125µg mL-1. At the maximum concentration examined (125μg mL-1), only ET 323 
SWPC35, ET WPI, ET WP and ET DW significantly (P<0.05) reduced adherence of 324 
S. salivarius to S-HA relative to the control (P<0.05). 325 
3.2 Growth Assays 326 
ET SWPC80 was found to significantly (P<0.05) inhibit growth of S. sobrinus and S. 327 
salivarius at all concentrations examined (Figure 2). Previous work in this laboratory 328 
demonstrated that ET SWPC80 significantly inhibited growth of the highly cariogenic 329 
microorganism S. mutans (Halpin et al., 2011), with no other enzyme-treated whey 330 
product exhibiting an antibacterial effect against this microorganism (O’Connor et al., 331 
2006). Therefore, in the present study only ET SWPC80 was assessed for its 332 
antibacterial activity against S. sobrinus and S. salivarius. The percentage growth 333 
inhibition was calculated using formula (1) described earlier (section 2.6). A time 334 
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point for each Streptococcus was chosen, depending on the time taken for the 335 
particular microorganism to reach mid-stationary phase. For S. sobrinus and S. 336 
salivarius 10 hours and 9 hours incubation were chosen, respectively. Growth was on 337 
average inhibited by 85.6% ± 5.9 for S. sobrinus at all concentrations. ET SWPC80 338 
was less effective at inhibiting growth of S. salivarius when compared to inhibition 339 
levels observed for S. sobrinus. However, growth was nevertheless inhibited by an 340 
average of 50.6% ± 4.9 at all concentrations. Growth inhibition was significant at all 341 
concentrations for both streptococci relative to control growth (P<0.05). 342 
4. Discussion                     343 
The present study has shown that dairy powders can inhibit adherence of S. 344 
sobrinus and S. salivarius to HA. The dairy powders were used firstly in their 345 
untreated forms, and their anti-adhesion activity was again evaluated following 346 
incubation with porcine pancreatic lipase (PPL). Both S-HA and PBS-HA models 347 
were employed, to reflect the tooth surface in the presence and absence of saliva, 348 
respectively. The S-HA model represents ‘normal’ conditions in the mouth, while the 349 
PBS model system reflects conditions where saliva production is impaired (‘dry 350 
mouth’ or xerostomia). In cases of xerostomia, an individual can experience severe 351 
instances of dental caries. The occurrence of dry mouth is a well recognised clinical 352 
problem in adults and children, and essentially occurs when the resting salivary flow 353 
rate is less than that of fluid loss from the mouth (Walsh, 2008). This condition can be 354 
due to use of certain medications (such as those prescribed for hypertension), 355 
radiation treatment of the head and neck, or can be incurred by patients with aplasia of 356 
the salivary glands (Sjogren’s syndrome) (Loesche, 1986, Johansson, 2002). In the 357 
present study, UT SWPC80, UT AWPC80, UT BMP and UT CP were the most 358 
effective inhibitors of adhesion of both S. sobrinus and S. salivarius to HA in the 359 
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absence of saliva, and thus may be useful ingredients in the formulation of a dairy-360 
based saliva substitute. In addition, such dairy powders capable of inhibiting 361 
adherence of streptococci to oral surfaces may help reduce the occurrence of focal 362 
oral infections, as introduction of viridans streptococci resident in the oral cavity into 363 
the bloodstream can lead to infections such as bacteremia (Gendron et al., 2000). This 364 
occurrence is particularly problematic for patients experiencing neutropenia (Prabhu 365 
et al., 2004). 366 
The level of ‘control’ adhesion for both S. sobrinus and S. salivarius varied 367 
greatly between PBS-HA and S-HA model systems. In the presence of saliva, UT 368 
SWPC80, UT AWPC80, UT WPI and UT CP were the most effective inhibitors of S. 369 
sobrinus adhesion to S-HA. However, all UT dairy powders (with the exception of 370 
SWPC35 and WPI) significantly reduced adherence of S. salivarius to S-HA 371 
(P<0.05). The findings of the present study are difficult to explain, as different levels 372 
of anti-adhesion activity were observed for each of the of dairy powders against S. 373 
sobrinus and S. salivarius, and the level of inhibition also varied depending on 374 
whether PBS-HA or S-HA models were used. A possible reason for the varied levels 375 
of efficacy exhibited by the dairy powders against S. sobrinus and S. salivarius may 376 
be due to the different adherence mechanisms of these strains. S. sobrinus (a member 377 
of the mutans streptococci) possesses a surface adhesin (SpaA) (Tokuda et al., 1990) 378 
and genes capable of producing glucosyltransferases (Gilmore et al., 1990), whereas 379 
strains of S. salivarius (which is not a member of the mutans streptococci) contain 380 
proteinaceous components associated with a fibrillar layer outside the cell wall, 381 
referred to as the ‘fuzzy coat’. This fuzzy coat is believed to mediate attachment of S. 382 
salivarius to host surfaces (Weerkamp et al., 1986). Thus, it is not surprising that the 383 
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dairy powders (and enzyme-treated versions thereof) do not interact with the different 384 
surface proteins of these two streptococci in a similar manner.  385 
In general, enzyme-treatment with PPL reduced the anti-adhesion efficacy of 386 
the dairy powders in both PBS-HA and S-HA assays, but the degree of reduction was 387 
less apparent for the latter. A possible reason for this may be interactions occurring 388 
between constituents of the hydrolysates and components of saliva e.g. salivary 389 
proteins or peptides. However, this is merely speculative and further research would 390 
be required if the exact cause were to be determined. Of the enzyme-treated dairy 391 
powders, ET SWPC80, ET AWPC80 and ET BMP were found to be the most 392 
effective inhibitors of S. sobrinus adherence to S-HA. The majority of ET powders 393 
appeared to reduce adherence of S. salivarius to S-HA, but this may have been due to 394 
a non-specific protein effect, as egg albumin was also observed to reduce S. salivarius 395 
adherence to S-HA, by about the same amount.  396 
While the way in which the dairy powders used in this study are inhibiting 397 
adherence of streptococci to HA has not yet been elucidated, protein adsorption 398 
experiments performed previously by this research group indicated that proteins 399 
present in the dairy powders were associating with the HA beads (Halpin et al., 2011). 400 
This is likely to be contributing to the reduction in streptococcal adherence, as the 401 
highest level of protein association was observed for UT AWPC80, which was also 402 
the most effective inhibitor of streptococcal adherence to PBS-HA. However, it is 403 
acknowledged in the context of such complex natural products that this may not be 404 
the sole factor involved in inhibiting the adherence of streptococci to HA. In addition, 405 
it should be noted that the less effective inhibitors were those which were lowest in 406 
fat.  407 
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Another aspect of the present study was to determine the effect of ET 408 
SWPC80 on the growth of S. sobrinus and S. salivarius. This hydrolysate inhibited 409 
growth of these cariogenic bacteria by up to 85% at concentrations as low as 0.6mg 410 
mL-1 (P<0.05). The crude PPL used in the present study is known to contain both 411 
proteases and lipases (Birner-Grunberger et al., 2003), and it may be that enzyme 412 
treatment of the dairy powders used in the present study releases both peptides and 413 
free fatty acids that are inactive within the untreated material. Thus, the component(s) 414 
of ET SWPC80 contributing to the observed antibacterial activity against S. sobrinus 415 
and S. salivarius may on one hand be antibacterial peptides derived from whey 416 
proteins such as β-lactoglobulin, α-lactalbumin or lactoferrin, as these proteins are 417 
known to harbour antibacterial peptides that can be released by proteolysis (Lopez-418 
Exposito and Recio, 2006). Alternatively, the antibacterial activity could be due to 419 
peptides cleaved from the glycomacropeptide (GMP), which is present in sweet whey 420 
products due to the action of chymosin on κ-casein. A study by Malkoski et al. (2001) 421 
showed that kappacin, a non-glycosylated, phosphorylated form of κ-casein, exhibited 422 
significant antibacterial activity against oral pathogens. In addition to the peptide 423 
hypothesis, it is possible that free fatty acids present in SWPC80 following enzyme-424 
treatment may have contributed to the antibacterial activity of this hydrolysate. 425 
Previous work in this laboratory confirmed the presence of butyric (C4) and caproic 426 
(C6) acids in SWPC80 after digestion with PPL (Halpin et al., 2011), and it is possible 427 
that other fatty acids were present after hydrolysis. However, the exact mechanism of 428 
action for the antibacterial activity of ET SWPC80 remains to be elucidated. 429 
Nonetheless, the action of PPL on SWPC80 produced an effective antibacterial agent 430 
possessing potent antimicrobial activity against caries-causing streptococci.  431 
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5. Conclusion  432 
This study has demonstrated that UT dairy powders, in particular sweet and 433 
acid WPC80 are effective inhibitors of streptococcal adhesion to buffer-coated and 434 
saliva-coated HA. Thus, dairy powders, which are readily available and relatively 435 
inexpensive materials, may be suitable dental caries-protective agents for both normal 436 
mouth conditions and individuals suffering from xerostomia. The anti-adhesion 437 
properties of these dairy powders against streptococci may also potentially reduce 438 
occurrence of more serious infections such as bacteremia as a consequence. In 439 
addition, it is evident from this study that ET SWPC80 is an effective antimicrobial 440 
agent active against S. sobrinus and S. salivarius. However, future work is necessary 441 
in order to establish which specific components of the different products are 442 
responsible for the observed inhibition, and also to examine whether theextend the 443 
observations of the present study to the oral cavity; thereby and establishing the 444 
efficacy of dairy products as therapeutic products in vivo. 445 
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Figure 1: Standard curves of relative fluorescent units (RFU) Vs colony forming 602 
units per millilitre (CFU mL-1) for (a) S. sobrinus and (b) S. salivarius. 603 
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 614 
Figure 2: Effects of enzyme-treated Sweet WPC80 on the growth of (a) S. sobrinus 615 
and (b) S. salivarius, at 5mg mL-1 (○), 2.5mg mL-1 (□), 1.25mg mL-1 (Δ), 0.6mg mL-1 616 
(●) and control growth in the absence of inhibitor (■). (Data= mean ± standard 617 
deviation, n=4). 618 
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Table 1: Compositional analysis of dairy powders used in this study (%). 627 
Dairy 
Powder 
Protein Fat Moisture Ash Lactose 
SWPC80 75.5 8 7.5 3 6 
AWPC80 78.2 7.7 6.3 5.9 1.9 
SWPC35 34.3 3.4 5.4 6.2 50.7 
WPI 86.6 0.1 5.8 2.6 4.9 
WP 12.5 1 3.1 9.5 73.9 
DW 13 1.8 3.5 0.8 80.9 
BMP 30.2 10.8 3.9 6.9 48.2 
CP 16.4 49.1 2.1 4.5 27.9 
Abbreviations: SWPC80= Sweet Whey Protein Concentrate 80, AWPC80= Acid 628 
WPC80, SWPC35= Sweet Whey Protein Concentrate 35, WPI= Whey Protein Isolate, 629 
WP= Whey Powder and DW= Demineralised whey, BMP= Buttermilk Powder, CP= 630 
Cream Powder. 631 
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Table 2: Proportion of S. sobrinus (%) not adhering to PBS-HA in the presence of dairy powders at various concentrations. 
 Untreated Enzyme-treated 
μg mL-1 Control* 31.25 62.5 125 31.25 62.5 125 
 28 ±7.1(w)       
SWPC80  33.7±3.6a,b,c (w) 63 ±3.1a (x) ¥ 91 ±3.2a,b (y) ¥ 31 ±5.6a (w,x) 32.2 ±5.9a,b (w,x) 40.3 ±7.3a (x) 
AWPC80  90.7 ±6.1d (x) ¥ 99.6 ±0.8b (x) ¥ 100 ±4.7a (x) ¥ 45.4a  44.7b,c 39.8a,b 
SWPC35  34.6 ±6.2a,b (w) 44.5 ±9c (x) 66.8 ±6.8c (y) ¥ 35.1 ±18.9a (w) 27.7 ±4.9b (w) 34.5 ±9.8a,b,c (w) 
WPI  23.9 ± 4.2c (w) 31.4 ±5.6d (w) 43 ±6.7d,e (x) ¥ 34.6 ±11.9a (w) 30.1 ±7.2b (w) 25.2 ± 2.8b,c (w) 
WP  26.9 ±4.1b,c (w) 32 ±5d (w,x) 37.5 ±4.7d,e (x) 24a 23.8b 23.5c 
DW  30.4 ±3.2a,b,c (w) 32.4 ±4.7d (w) 44.7 ±9d (x) ¥ 29.3 ±0.9a (w) 24.5 ±2b (w) 26.4 ±3.9a,b,c (w) 
BMP  73.1 ±4.4e (x) ¥ 85.1 ±5e (y) ¥ 98.4 ±3.2a,b (z) ¥ 45.9 ±4.8a (x) 56 ±3.6c (x,y) 65.4 ±10.3d (y,z) 
CP  47.3 ±6.3f (x) ¥ 67.4 ±7a (y) ¥ 90.1 ±8.6b (z) ¥ 31.3 ±3.3a (w,x) 34 ±7.1a,b (w,x) 39 ±4.4a,b (x,y) 
Egg Albumin†  38.9 ±11.6a,f (x) 37.1 ±7.6c,d (x) 33.8 ±5.8e (w,x)    
Footnotes: PBS-HA= phosphate-buffered saline-coated hydroxylapatite. 
Data presented represent the means (± SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly 
(P<0.05) different.  Data within each row bearing different superscripts (x,y,z) show significant (P<0.05) differences between concentrations 
within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript ‘w’. 
¥ denotes significant difference (P<0.05) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.  
*n=52, †= egg albumin is included for the sake of comparison only as a protein control.  
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Table 3: Proportion of S. sobrinus (%) not adhering to S-HA in the presence of dairy powders at various concentrations. 
 Untreated Enzyme-Treated 
μg mL-1 Control* 31.25 62.5 125 31.25 62.5 125 
 45.8 ±10.8(w)       
SWPC80  72.1 ±8.7a (x) 87 ±9.7a (x) 87 ±10.2a,b (x) 82.9 ±12a (x) 89.3 ±8.2a (x) 96.8 ±5.6a,b (x) 
AWPC80  83.4 ±1.2b (x) ¥ 88.2 ±2.3a (x) 89.1 ±9.7a (x) 60.3 ±9.1a,b,c (x) 81.4 ±7.4a,b (y) 100a (z) 
SWPC35  38 ±6c (w) 47.7 ±7.1b,c (w,x) ¥ 62.3 ±8.3c,d (x) 57.4 ±23.7b,c (w,x) 68.2 ±8.3b,c,d (x) 76 ±15b,c,d (x) 
WPI  64.3 ±3.1a,d (x) ¥ 78.7 ±4.9a,d (x,y) ¥ 89.6 ±4.8a (y) ¥ 47.3 ±5.8b,c (w) 54.6 ±6.6d,e (w) 58.5 ±14c,d,e (w) 
WP  27.4 ±4.3c (x) ¥ 41 ±13.3c (w,x,y) 53.3 ±16.8d,e (w,y) 55.4 ±10.8b,c (w,x) 63.4 ±10.6b,c,d (x,y) 76.1 ±2.8b,c,d (y) 
DW  36.7 ±4.2c (w) 41.8 ±9.7c (w) 44.3 ±9.3e (w) 37.5 ±10.3c (w) 39.6 ±11e (w) 48.4 ±11e (w) 
BMP  52.1 ±12.le (w) 61.9 ±14.7b,d (x) 69.4 ±10.4b,c,d (x) 62.1 ±18.7a,b (x) 78.9 ±13.1a,b,c (x) 80.l ±16.7a,b,c (x) 
CP  57.1 ±6.6d,e (w) 62.6 ±3.7b,d (x) 71.1 ±9.2a,b,c,d (x) 62.2 ±10.8a,b (x) 58.1 ±20.5c,d,e (w,x) 55.8 ±22.2d,e (w,x) 
Egg Albumin†  51.2 ±5.5e (w,x) 65.5 ±12.1b,d (x,y) 76.1 ±7.4a,b,c (y)    
Footnotes: S-HA= saliva-coated hydroxylapatite. 
Data presented represent the means (± SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly 
(P<0.05) different.  Data within each row bearing different superscripts (x,y,z) show significant (P<0.05) differences between concentrations 
within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript ‘w’. 
¥ denotes significant difference (P<0.05) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.  
*n=53, †= egg albumin is included for the sake of comparison only as a protein control.  
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Table 4: Proportion of S. salivarius (%) not adhering to PBS-HA in the presence of dairy powders at various concentrations. 
 Untreated Enzyme-Treated 
μg mL-1 Control* 31.25 62.5 125 31.25 62.5 125 
 40.7 ±10.6(w)       
SWPC80  61.3 ±8.2a,b (x) 75 ±8a,b,c (x) ¥ 89.5 ±2.8a,b,c,d (y) ¥ 50.9 ±9.8a,b (w,x) 53.2 ±6.6a (x) 56.6 ±5.4a (x) 
AWPC80  90.4 ±6.7c (x) ¥ 98.6 ±1.8d (x) ¥ 97.8 ±4.3a (x) ¥ 40.4 ±4.4a,b (w) 40.9 ±5.7a,b (w) 39.7 ±8a,b (w) 
SWPC35  63.2 ±9a,b (x) 69.3 ±6.4a,b,c (x) ¥ 77.2 ±3.6d (x) ¥ 47.1 ±10.7a,b (w) 42.2 ±8a,b (w) 39.4 ±5.6a,b (w) 
WPI  65.4 ±16.5a,b (x) 84.8 ±15.7a,b,d (y) 94.2 ±5.3a,b (y) ¥ 26.2b 25.6b 27.2b 
WP  86.5 ±12.7c,d (x) ¥ 74.3 ±16.8a,b,c (x) 84 ±15.7b,c,d (x) 39.3 ±9.8a,b (w) 51 ±24.5a,b (w) 50.1 ±21.4a,b (w) 
DW  51.2 ±14.3b (w) 67.3 ±17.7b,c (x) 78.7 ±12.8c,d (x) ¥ 38.4a,b 44.1a,b 30.5b 
BMP  85.6 ±9.3c,d (x) ¥ 89.7 ±7.7a,d (x) ¥ 95.6 ±3.1a,b (x) ¥ 44.8 ±11.6a,b (w) 41.6 ±8.2a,b (w) 39.7 ±11a,b (w) 
CP  71.1 ±9.3a,d (x) 83.3 ±11.6a,b,d (x,y) ¥ 90.8 ±7a,b,c (y,z) ¥ 64.2 ±19.1a (x) 49.7 ±11.8a,b (w,x,y) 47 ± 15.3a,b (y) 
Egg Albumin†  60.6 ±10.1a,b (x) 56.7 ±16.2c (x,y) 41.6 ±1.8e (w,y)    
Footnotes: PBS-HA= phosphate-buffered saline-coated hydroxylapatite. 
Data presented represent the means (± SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly 
(P<0.05) different.  Data within each row bearing different superscripts (x,y,z) show significant (P<0.05) differences between concentrations 
within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript ‘w’. 
¥ denotes significant difference (P<0.05) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.  
*n=59, †= egg albumin is included for the sake of comparison only as a protein control. 
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Table 5: Proportion of S. salivarius (%) not adhering to S-HA in the presence of dairy powders at various concentrations. 
 Untreated Enzyme-Treated 
μg mL-1 Control* 31.25 62.5 125 31.25 62.5 125 
 66.2 ±15.7(w)       
SWPC80  95.7 ±3.4a (x) 87.1 ±5.7a (x) 90.9 ±6.1a (x) ¥ 91.1 ±3.9a,b (x) 83.8 ±6.5a,b (w,x) 68.3 ± 8.3a,b (w,x) 
AWPC80  95.7 ±7.4a (x) 93.3 ±5.8a (x) 98.7 ±2.2a (x) ¥ 89.7 ±13.6a,b (x) 89.2 ±12.7a,b (x) 60.8 ±7.7a,b (w,y) 
SWPC35  69.2 ± 18.1b (w) 77.8 ±22.7a (w) 79.7 ±18.3a (w) 83.8 ±3.9a,b,c (x) 91.4 ±9.9a (x) 89.5 ±9.6a (x) 
WPI  65 ± 25b (w) 70.5 ±22.8a (w) 77 ±19.5a (w) 93.6 ±6.5a (x) 94.7 ±12.5a (x) 96.4 ±5.5a (x) 
WP  80.7 ±10.5a,b(w,x) 86.2 ±1.3a(x) 87.7 ±13.8a(x) 80.8 ±5.7a,b,c (w,x) 83.4 ±8.9a,b (w,x) 91.1 ±12.4a (x,y) 
DW  81.2 ±15.2a,b (w,x) 83.8 ±14.2a (w,x) 85 ±18.6a (x) 84 ± 9.9a,b,c (w,x) 86.7 ±7a,b (x) 95.2 ±6.7a (x) 
BMP  87.9 ±7.9a,b (x) 84.1 ±15.1a (x) 91.3 ±10.2a (x) 90.1 ±2.7a,b (x) 70.3 ±13.2a,b (w,x) 52.2 ±33.6b (w,y) 
CP  67 ±13.6b (w,x) 72.1 ±8.4a (w,x) 88.2 ±13.1a (x) 62.6 ±38.6c (w) 63 ±33.2b (w) 69.8 ±49.7a,b (w) 
Egg Albumin†  66.2 ±12.5b (w) 75.8 ±9.2a (w) 76.9 ±8.2a (w)    
Footnotes: S-HA= saliva-coated hydroxylapatite. 
Data presented represent the means (± SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly 
(P<0.05) different.  Data within each row bearing different superscripts (x,y,z) show significant (P<0.05) differences between concentrations 
within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript ‘w’. 
¥ denotes significant difference (P<0.05) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.  
*n=57, †= egg albumin is included for the sake of comparison only as a protein control. 
 
